TY  - JOUR
AU  - Baertsch, Marc-Andrea
AU  - Schlenzka, Jana
AU  - Lisenko, Katharina
AU  - Krzykalla, Julia
AU  - Becker, Natalia
AU  - Weisel, Katja
AU  - Noppeney, Richard
AU  - Martin, Hans
AU  - Lindemann, Hans W
AU  - Haenel, Mathias
AU  - Nogai, Axel
AU  - Scheid, Christof
AU  - Salwender, Hans
AU  - Fenk, Roland
AU  - Graeven, Ullrich
AU  - Reimer, Peter
AU  - Schmidt-Hieber, Martin
AU  - Goerner, Martin
AU  - Schmidt-Wolf, Ingo G H
AU  - Klein, Stefan
AU  - Ho, Anthony D
AU  - Goldschmidt, Hartmut
AU  - Wuchter, Patrick
TI  - Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
JO  - European journal of haematology
VL  - 99
IS  - 1
SN  - 0902-4441
CY  - Oxford
PB  - Wiley-Blackwell
M1  - DKFZ-2017-01329
SP  - 42 - 50
PY  - 2017
AB  - Analysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM).Peripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2 g/m(2) daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG).Mobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen patients received additional pre-emptive/rescue administration of plerixafor. Stem cell collection was successful (≥2×10(6) CD34+ cells per kg bw) in 77
LB  - PUB:(DE-HGF)16
C6  - pmid:28370401
DO  - DOI:10.1111/ejh.12888
UR  - https://inrepo02.dkfz.de/record/124452
ER  -